The Conference on Retroviruses and Opportunistic Infections (CROI) took place this year in Denver Colorado on March 3-6. This conference is used to provide a forum for basic scientists and clinical investigators to present, discuss, and critique their investigations into the epidemiology and biology of human retroviruses and associated diseases.
This year, UNC was proud to have over 65 abstracts in the Invited Sessions Presentations, and a few of our UNC CFAR faculty participated in oral presentations and talks as well.
On Wednesday, Clinical Core Director Joe Eron gave an oral abstract presentation on “Lenacapavir Plus bNAbs for People with HIV and Sensitivity to Either Teropavimab or Zinlirvimab.” Dr. Eron’s presentation suggested that broadly neutralising antibodies may be partners for long-acting antiretrovirals. In a phase 1b study of lenacapavir (LEN) plus teropavimab (TEP) and zinlirvimab (ZAB), among participants who were highly susceptible to either TAB or ZAB the combination of LEN+TAB+ZAB was safe and well tolerated.
Also on Wednesday, Nancie Archin, a Co-Lead for the ESI Cure HIV research group, moderated an oral abstract session titled “HIV Reservoir and Cure Strategies.” This session was focused on the latest research efforts to eliminate the reservoir, understand sex differences in HIV transmission and the reservoir, as well as testing exciting immune based approaches to control HIV infection and delay viral rebound.
While these were only two presentations mentioned here, UNC participated in many abstracts and presentations throughout the 3 days at CROI, and you can find more using the buttons below. UNC CFAR is honored to have a presence at CROI and are looking forward to seeing your cooperation in the future.
To see more of UNC at CROI, click here.
To gain access to all of the abstracts and presentations at CROI 2024, click here.